Douglas Morrow, MD
Surgery · Tarzana, CANPI 1790778959
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Organogenesis Inc. accounts for 73.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $713 and has fallen 67.0% since, to $235 in 2025.
Across 98 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$2K
- Smith+Nephew$470
- Kerecis Limited$157
- Next Science LLC$40
- KCI USA, Inc.$18
- Tactile Systems Technology Inc$14
- plus $24 from 2 others
What the payments were for
- Food & beverage$2,731100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 74 | $2,009 |
| Smith+Nephew | 15 | $470 |
| Kerecis Limited | 4 | $157 |
| Next Science LLC | 1 | $40 |
| KCI USA, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $14 |
| Molnlycke Health Care US, LLC | 1 | $12 |
| Tenex Health Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Apligraf$125
- Dermagraft$125
- Puraply/Affinity/NuTech$125
- GRAFIX PL$124
How this compares
$2,731 in reported general payments places this provider in the 55th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 11 | $555 |
| Clindamycin Hcl | 28 | $313 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 41 | $309 |
| Doxycycline Hyclate | 29 | $296 |
| Potassium Chloride | 17 | $226 |
| Cephalexin | 18 | $222 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $208 |
| Cefadroxil | 18 | $181 |
| Levofloxacin | 35 | $178 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 22 | $131 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $59 |
| Furosemide | 15 | $43 |
| Tramadol Hcl | 36 | $41 |
| Amoxicillin | 12 | $37 |
Paid to pharmacies, not to this prescriber.
Other surgery in Tarzana
- Timothy ChuterSan Francisco$8.8M
- Santiago HorganSan Diego$2.8M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
- Siew-Ming LeeFresno$1.3M
- Beemen KhalilPalo Alto$1.1M
- John LiphamLos Angeles$942K
- Alexander NedopilLodi$682K
- Barry GardinerSan Ramon$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.